Equities Analysts Offer Predictions for KROS Q2 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Research analysts at HC Wainwright raised their Q2 2025 earnings estimates for shares of Keros Therapeutics in a research note issued on Thursday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($1.28) for the quarter, up from their prior forecast of ($1.39). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($1.29) EPS, Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($6.07) EPS, FY2027 earnings at ($6.70) EPS, FY2028 earnings at ($4.62) EPS and FY2029 earnings at ($3.04) EPS.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the previous year, the business earned ($1.21) earnings per share.

Several other analysts also recently weighed in on KROS. Truist Financial dropped their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, April 9th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Wedbush reissued a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Finally, Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.67.

Keros Therapeutics Price Performance

KROS opened at $13.65 on Monday. The stock’s 50 day simple moving average is $12.20 and its 200 day simple moving average is $24.23. The firm has a market cap of $554.39 million, a price-to-earnings ratio of -2.62 and a beta of 1.32. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $72.37.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Keros Therapeutics by 31.1% in the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock worth $26,151,000 after purchasing an additional 609,212 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Keros Therapeutics in the 1st quarter worth about $490,000. Federated Hermes Inc. increased its stake in shares of Keros Therapeutics by 882.3% in the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after acquiring an additional 1,099,519 shares in the last quarter. Corton Capital Inc. purchased a new position in Keros Therapeutics during the 1st quarter valued at about $186,000. Finally, CWM LLC lifted its position in Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after acquiring an additional 2,641 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.60% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.